Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of V181 dengue vaccine in healthy adults aged 59 years and older
MOH_2023-09-18_012943Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dengue fever comparing V181 with Placebo (2 arms). Primary endpoints: Solicited injection-site adverse events, Solicited systemic adverse events and 2 more. Started Dec 2023; status: completed.
02
Drugs
TetraVax-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on MOH_2023-09-18_012943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-18_012943.